Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
Fulcrum Therapeutics, Inc. (FULC)
Last fulcrum therapeutics, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
? On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ? ? Restart of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) underway ? ? Conference call and webcast scheduled for 8:00 a.m. ET today ? CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today reported financial results for the fourth quarter and full year of 2023 as well as an update to the business. “In 2023, we took important steps to advance our two key clinical programs which included completing enrollment for the Phase 3 REACH trial of losmapimod in FSHD and resolving the clinical hold for our Phase 1b PIONEER trial of pociredir in SCD,” said Alex C. Sapir, Fulcrum’s president and chief executi
Show less
Read more
Impact Snapshot
Event Time:
FULC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FULC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FULC alerts
High impacting Fulcrum Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FULC
News
- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $23.00 price target on the stock.MarketBeat
- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $16.00 to $14.00. They now have an "outperform" rating on the stock.MarketBeat
- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.MarketBeat
- Sanofi to make €1bn biomanufacturing investment in France [Yahoo! Finance]Yahoo! Finance
- Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely? [Yahoo! Finance]Yahoo! Finance
FULC
Earnings
- 5/13/24 - Beat
FULC
Sec Filings
- 5/13/24 - Form 10-Q
- 5/13/24 - Form 8-K
- 5/9/24 - Form 4
- FULC's page on the SEC website